Since approved in 2014, tucidinostat was considered as a next-line and subsequent therapy for PTCL clients in China. Medical trials and preclinical studies in multiple hematological malignancies and good tumors is in development. The goal of the present section IIb examine was To guage the efficacy and protection of tucidinostat https://jenningsq887doa1.mappywiki.com/user